Kornimate/medical-research-clean huggingface dataset:
eye movements and reading disabilities

Conditions: Reading Disability; Dyslexia

Summary: the mechanism of the eye movement anomalies seen in dyslexic patients is not well defined. some optometrists use observational eye movement tests as screening devices for dyslexia and advocate eye movement therapy as a treatment option for dyslexia. the reliability of the clinical eye movement tests and the efficacy of the eye movement therapies have not been determined. saccades are the fast eye movements that move our eyes from one word to the next when we read. the eye movement recordings from patients diagnosed with reading disorders, extra ocular muscle imbalances and control patients (no learning disability or eye movement disorder) will be analyzed and compared. the sensitivity and specificity of detecting reading disorders will be determined for the visagraph iii and the readalyzer. although these clinical tests are frequently used to diagnose saccadic inaccuracies and diagnose dyslexia in school aged children, the validity of these clinical screening tests has not been determined.


Eligibility criteria:
inclusion criteria: * 1. age 7 to 13 (must be in at least 2nd grade, but not higher than 8th grade) 2. complete ophthalmic examination performed by a pediatric ophthalmologist and orthoptist. 3. all ocular structures must be within normal limits. 4. best corrected visual acuity must be equal to or better than 20/30 in each eye. 5. group 1: 1. children with a reading disability must be given the diagnosis by a clinical educational specialist, educational psychologist or neuro-behavioral psychologist. 2. children with a reading disability may not have any ophthalmic anomaly determined by testing as described above. this includes but is not limited to amblyopia, strabismus, nystagmus, or any organic disease. 6. group 2 a. eye movement disorder confirmed by testing by a pediatric ophthalmologist and/or orthoptist b. all other ocular structures must be within normal limits (including visual acuity). 7. group 3: 1. no evidence of reading disability, attention deficit disorder or ocular anomaly, including eye muscle or movement disorder as specified above. exclusion criteria: * 1. myopia more than - 6.00 diopters (spherical equivalent) in either eye. 2. hyperopia more than + 6.00 diopters (spherical equivalent) in either eye. 3. history of vision therapy or orthoptic treatment 4. any ocular anomaly with the exception of eye movement disorder for group 2.
brain and voice signatures in teachers

Conditions: Voice Disorders; Voice Fatigue

Summary: primary muscle tension dysphonia voice disorder with symptoms of vocal strain and vocal fatigue is common and can have a significant negative impact on quality of life. yet, primary muscle tension dysphonia's causes are unknown precluding precise diagnostic classification. stress and personality are thought to play a role and thus, the project aims to determine the practical and clinical effect of stress on the control of voice and speech in the brain. participants are female early career teachers and student teachers with symptoms of vocal fatigue, as well as control participants without vocal fatigue, who perform speech tasks on two different occasions. neural (imaging of brain), psychobiological (saliva, personality), and voice and speech (muscle activity of voice muscles on the neck with surface sensors, audio recordings) data will compare reactivity patterns of teachers who are stressresponders with those who are nonresponders as well as control participants. the central hypothesis is that voice box stress responders have heightened emotion-motor activations involving the emotional voice production pathway, which correlate with changes in voice muscle activity in the anterior neck. the results will provide fundamentally missing data in our understanding of the role of stress in vocal complaints and will yield new insights about the neural underpinnings of primary muscle tension dysphonia. the study findings will have a significant impact on how clinicians identify so-called laryngoresponders to help them prevent voice disorders.


Eligibility criteria:
inclusion criteria: teachers (max. 10 years full-time) or student teachers in good health between 21 and 39 years with symptoms of vocal fatigue. control participants in good health between 21 and 39 years without symptoms of vocal fatigue. exclusion criteria: * lefthandedness * smoking (past 5 years) * known changes of the vocal folds (e.g., vocal fold nodules), vocal fold paralysis, surgeries on the larynx or thryoid or current organic or neurological changes of the vocal folds or vocal function per videoendoscopy and -stroboscopy of the larynx * history of voice therapy * hoarseness * respiratory illness, allergies (respiratory, silver), reflux or asthma at time of participation * hearing disorder or hearing aids * psychological, neurological or endocrinological disorders * psychotropic or steorid medications * body mass index \> 30 * indications against mri such as metail parts in or on the body (e.g., permanent dental prostheses or braces, screws, prostheses, piercings or large tattoos * nearsightedness \> -5 diopters, if only glasses are worn * claustrophobia * pregnancy

Keywords: voice disorders vocal fatigue occupational voice disorders stress reactivity vocal control laryngeal motor cortex teachers speech motor control voice motor control
flex®-dcb dialysis access stenosis study

Conditions: Arteriovenous Fistula

Summary: this prospective, single arm, single-center study is designed to evaluate the performance of the flex scoring catheter®/poba/dcb in a-v access circuits.


Eligibility criteria:
inclusion criteria: * patient is legally competent, has been informed of the study, voluntarily agrees to participate, and has signed the informed consent form. * arteriovenous fistula is located in the arm. * native av fistula / graft was created ≥ 30 days prior to the initial procedure and has undergone at least one hemodialysis sessions. * venous stenosis of the av fistula / graft with the target lesion located from the anastomosis to the axillosubclavian junction and an abnormality attributable to the stenosis as defined by k/doqi guidelines. * patients with a dysfunctional or thrombosed hemodialysis access and a \>50% stenosis, regardless of prior treatment (all types of lesion and access failure) * if av access is thrombosed, must undergo a successful thrombectomy with minimal residual thrombus. * intended target lesion or if a tandem lesion can be treated with ≤120 mm of dcbs in length. exclusion criteria: * life expectancy \< 9 months * women who are pregnant, lactating, or planning on becoming pregnant during the duration of the study. * the hemodialysis access is located in the leg. * patient has more than two lesions in the access circuit. * patient has a secondary non-target lesion that cannot be successfully treated * target lesion is located central to the axillosubclavian junction. * surgical revision of the access site planned. * recent surgical interventions of the access site. * known allergy or sensitivity to iodinated contrast media, that cannot be adequately managed with pre- and post-procedure medication. * known allergy or sensitivity to paclitaxel. * patients who are taking immunosuppressive therapy, or routinely taking ≥ 10 mg of prednisone per day. * patients who have a medical condition, in the opinion of the investigator, that may cause the patient to be noncompliant to the protocol or confound the data. * patients anticipating a kidney transplant. * patients anticipating a conversion to peritoneal dialysis. * the patient has a stent located in the target or secondary non-target lesion. * patient has an active infection in the av access or a systemic infection. * known hyper-coagulable state * currently participating in an investigational drug, biologic, or device study. * previously enrolled in this study.

Keywords: arteriovenous fistula vascular fistula scoring fistula cardiovascular disease
efficacy and safety of intravenous paracetamol in manament of labour pain

Conditions: Labor Pain

Summary: to compare between the use of single dose of paracetamol and pethidine hydrochloride intravenously in management of labour pains

investigators conducted a randomized clinical study included including 96 primiparous women admitted to obstetrics and gynecology department, menoufia university hospitals, starting the study from may 2019 to march 2020 to assess the use of paracetamol intravenously versus pethidine hcl intravenously in management of intrapartum pain. after obtaining approval from the local ethics committee, women who agreed to participate gave their signed informed consent after explanation of the trial benefits and hazards

Eligibility criteria:
inclusion criteria: * primiparous * aged 18-35 years, * term live singleton pregnancy, * vertex presentation, * spontaneous onset of labor at term 37-42 weeks gestation, * in active phase of of 1st stage of labour (cervix dilatation 3- 4 cm). exclusion criteria: clinical evidence of cephalopelvic disproportion * use of any kind of analgesia prior to study * any medical disorder during pregnancy (liver or kidney impairment) * induction of labor, intrauterine fetal death * evidence of fetal distress * antenatal diagnosis of congenital malformation * previous history of hypersensitivity to either drug * extremes of age (i.e. below 18 or above 35) * multiple pregnancies * cervical dilatation more than 6 cm.
peptide vaccination in treating patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: the purpose of this study is to evaluate the safety and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

we recently identified three hla-a2402-restricted epitope peptides (ttk protein kinase (ttk), lymphocyte antigen 6 complex locus k (ly6k), and insulin-like growth factor (igf)-ii mrna binding protein 3 (imp-3)) derived from novel cancer-testis antigens (cta) for the development of immunotherapies against esophageal squamous cell carcinoma (escc), and reported that the pre-existence of specific t cell responses to these epitope peptides were frequently seen in escc patients. then, we performed phase i vaccination trial using multi-epitopes involving ttk, ly6k, and imp-3 peptides for locally advanced, recurrent or metastatic esophageal squamous cell carcinoma who had failed for the standard therapy. each of three hla-a2402-restricted epitope peptides mixed with ifa were injected every week at five round. primary endpoints were to evaluate the safety and feasibility of the therapy. secondary endpoints were to investigate the immunological monitoring and clinical effect.

Eligibility criteria:
inclusion criteria: * disease characteristics 1. locally advanced, recurrent or metastatic esophageal squamous cell carcinoma who had failed for the standard therapy patients characteristics 1. ecog performance status 0-2 2. age≧20 years, 80≦years 3. wbc≥ 2,000/mm³ platelet count ≥ 75,000/mm³ total bilirubin ≤ 2.0 x the institutional normal upper limits ast, alt, alp ≤ 2.5 x the institutional normal upper limits creatinine ≤ 1.5 x the institutional normal upper limits 4. patients must be hla-a2402 5. able and willing to give valid written informed consent exclusion criteria: 1. pregnancy (women of childbearing potential: refusal or inability to use effective means of contraception) 2. breastfeeding 3. serious bleeding disorder 4. serious infections requiring antibiotics 5. concomitant treatment with steroids or immunosuppressing agent 6. decision of unsuitableness by principal investigator or physician-in-charge

Keywords: epitope peptide, ctl, esophageal cancer, vaccination
effect of rectus sheath block on diaphragmatic function after elective upper abdominal surgery

Conditions: Acute Pain

Summary: this study will be undertaken to investigate the respiratory and analgesic effects of ultrasound guided rectus sheath block analgesia after elective abdominal surgery with midline incision.

a major proportion of pain experienced by patients undergoing abdominal surgeries is due to somatic pain signals derived from the abdominal wall. the central portion of anterior abdominal wall components (skin, muscles and parietal peritoneum) is innervated by sensory neurons branching from the anterior rami of spinal nerves t7 to t1. these neurons lie between the rectus abdominis muscle and posterior rectus sheath, and pierce the rectus muscle close to the midline. the tendinous intersections of the rectus muscle do not fuse with the posterior rectus sheath, thereby allowing the injectate to spread cephalo-caudally within this potential space. rectus sheath (rs) block has been described for any midline abdominal incisions (epigastric and umbilical hernia repairs). as visceral pain becomes attenuated by the 2nd postoperative day, rectus sheath block can also be administered for midline laparotomy. however, the effects of rectus sheath block analgesia on the respiratory function after abdominal surgery with midline incisions are still under investigation.

Eligibility criteria:
inclusion criteria: * age: 18-50 years. * sex: both males and females. * bmi\< 30kg/m2. * asa physical status: 1, ii and iii. * elective abdominal surgery with midline incisions. exclusion criteria: * patient refusal. * infection at injection site * coagulation disorders. * allergy to study medications. * pregnancy. * respiratory tract infection within the last 2 weeks. * urgent abdominal surgery
single-step versus sequential media in preimplantation embryo development and pregnancy rates

Conditions: Infertility

Summary: sequential culture media were introduced in order to meet the changing requirements of the developing embryo in vitro. however, there has been renewed interest in the use of single-step media, which allow the embryo itself to choose the necessary nutrients while maintaining a more stable culture environment. previous studies suggest that sequential media do not appear superior to single-step media.

sequential culture media were introduced in order to meet the changing requirements of the developing embryo in vitro. however, there has been renewed interest in the use of single-step media, which allow the embryo itself to choose the necessary nutrients while maintaining a more stable culture environment. previous studies suggest that sequential media do not appear superior to single-step media. the current study will include 2 rcts: rct 1: random allocation of sibling oocytes to compare embryo development and blastocyst formation rates in the two culture media compared. rct2: random allocation of patients in either global or origio media, to evaluate pregnancy rates.

Eligibility criteria:
inclusion criteria: * \<40 years of age * female infertility patients * at least 10 retrieved oocytes exclusion criteria: * 41 years or older * frozen-thawed oocytes/embryos * oocyte donation cycles
alfapump system post marketing surveillance registry

Conditions: Liver Cirrhosis; Refractory Ascites; Malignant Ascites

Summary: this is a post market surveillance registry to monitor the safety and performance of the alfapump system.


Eligibility criteria:
inclusion criteria: * refractory or recurrent ascites and liver cirrhosis or malignancy * written informed consent exclusion criteria: * \< 18 years * pregnant * not able to use the smart charger
korean chronic obstructive pulmonary disease(copd) assessment test validation study

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this is a cross-sectional validation study, designed to evaluate the discriminative validity of the chronic obstructive pulmonary disease assessment test translated in a local language in patients with chronic obstructive pulmonary disease.

the chronic obstructive pulmonary disease assessment test is a new questionnaire that has been developed recently to improve communication between doctors and patients. it is known to have good relationship with other measures of quality of life. for the wider application to practice, it has been translated into a local language in many countries.

Eligibility criteria:
inclusion criteria: subjects eligible for enrolment in the study must meet all of the following criteria: 1. type of subject: outpatients 2. informed consent: subjects must give their signed and dated written informed consent to participate. 3. gender: male or female 4. age: 40 years of age or older at a clinic visit 5. copd diagnosis: subjects with an established diagnosis of copd in the past 6 months or before. 6. tobacco use: smokers or ex-smokers with a smoking history of more than 10 pack years. exclusion criteria: 1. asthma: subjects with a current diagnosis of asthma. subjects with a prior history of asthma are eligible if copd is the current diagnosis. 2. lung diseases: subjects with current active respiratory disorders other than copd, e.g. lung cancer, tuberculosis. 3. non-compliance: unable to complete questionnaires

Keywords: chronic obstructive pulmonary disease(copd) copd assessment test(cat)
provide pre-approval single patient expanded access (compassionate use) of etrasimod for patients.

Conditions: Colitis, Ulcerative

Summary: provide pre-approval single patient expanded access (compassionate use) of etrasimod for patients.

in expanded access, treating physicians are the sponsors. expanded access requests from treating physicians may be submitted to www.pfizercares.com. availability will depend on location and country.

Eligibility criteria:
patient must be intolerant, have a contraindication or had inadequate response to at least 3 therapies available for ulcerative colitis (uc) in this country or provide a rationale of why therapy was not used.

Keywords: ulcerative colitis
a study to assess virtual reality by healthcare providers: a pilot study

Conditions: Anxiety; Burn Out

Summary: the purpose of this study is to evaluate the acceptability of using virtual reality intervention to help reduce anxiety and burnout symptoms and improve focus in the workplace.

the proposed investigation will apply two novel paradigms using proprietary virtual reality interventions designed to reduce anxiety and inattention. we will explore whether this intervention is safe and acceptable, and whether it can impact the stress, anxiety, and difficulty in focus of employees in the workplace. participants will view two different nature videos in two different formats. each video will be experienced through virtual reality or non- virtual reality.

Eligibility criteria:
inclusion criteria: * 18 years of age or older at the time of consent. * healthcare professional with the mayo clinic. * not pregnant by participant self-report at time of consent. * have the ability to provide informed consent. * have no contraindicated comorbid health conditions as determined by the clinical investigators. exclusion criteria: * currently (within the past 3 weeks) practicing mindfulness training on a weekly/regular basis. * currently (within the past 3 weeks) undergoing an additional program (e.g., complementary and alternative medicine \[cam\]) to improve quality of life. * currently (within 3 weeks) enrolled in another clinical or research program (e.g., cam) which impacts the patients' quality of life (qol), stress or anxiety. * currently has photosensitivity. * cannot tolerate virtual reality experiences. * an unstable medical or mental health condition as determined by the physician investigator (e.g., pre-existing eye strain, seizures, dizziness, nausea)

Keywords: anxiety burnout
efficacy and safety study of a low-carbohydrate tube feed in critically ill patients under insulin therapy

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: the purpose of this study is to determine the efficacy and safety of a diabetes-specific tube feed in comparison to an isocaloric, isonitrogenous standard enteral formula in critically ill patients receiving insulin treatment for blood glucose management.


Eligibility criteria:
inclusion criteria: * patients with spontaneous aneurysmal subarachnoid hemorrhage (sah) defined according to hunt and hess scale grade hh5 * requiring mechanical ventilation in the icu at the time of enrolment * enteral nutrition (en) in the icu at time of enrolment * if enrolment on day 3 of icu stay, en equal to or larger than 80% of total calories in case of supplementary parenteral nutrition (pn) with anticipated 100% en as of day 4 to 8 of icu stay * if enrolment on day 4 of icu stay, 100% en planned for at least 5 days from the time of enrolment * patients expected to stay in the icu for at least 5 days following enrolment * age 18 - 75 years * glycemic control with intravenous insulin therapy to maintain a target glucose range between 110 mg/dl and 150 mg/dl (6.1 and 8.3 mmol/l) * informed consent according to local regulations for decisionally impaired subjects exclusion criteria: * patients with septic shock at time of enrolment * participation in a clinical trial with any investigational product within 4 weeks before study * patients requiring a fibre free diet * total or supplementary parenteral nutrition (\> 20% of total calories) * known or suspected intolerance or allergy to any component of the study product(s), e.g. galactosemia * gastrectomy * postpyloric nutrition * any clinical condition not allowing enteral nutrition (e.g. emesis, severe reflux, severe diarrhea) * known severe heart failure (nyha class 4) * liver insufficiency / failure (male: alat \> 150 u/l; female: alat \> 120 u/l) * acute kidney failure (blood creatinine \> 2.5 mg/dl) * body mass index \ 35 kg/m² * known or suspicion of drug abuse * pregnant or breast feeding women * patients with diabetes mellitus type i exclusion after enrolment (withdrawal of subjects) * start of pn with more than 20% of total given energy amount/ day * insulin infusion stopped unexpectedly for \> 12h for non-nutritional reasons * discharge from icu * intolerable aes * major protocol violation * withdrawal of informed consent * discontinuation of study treatment for other reasons

Keywords: enteral nutrition tube feeding diet, carbohydrate-restricted diabetes aneurysmal subarachnoid hemorrhage blood glucose insulin